News brief­ing: British psy­che­del­ic in­vest­ment firm launch­es; Irish cell ther­a­py com­pa­ny gains ex­clu­sive li­cense op­tions

The first in­vest­ment fund in Britain sole­ly fo­cused on psy­che­del­ic health care has launched, and will draw un­capped ven­ture cap­i­tal through at least the first half of 2021.

Neo Ku­ma Ven­tures, a Lon­don-based firm found­ed in 2019, has an in­vest­ment the­sis fo­cused on clin­i­cal­ly-proven psy­che­del­ic med­i­cines which it be­lieves will hit the mar­ket in the next five years.

The firm said in a press re­lease that “rig­or­ous” clin­i­cal tri­als have shown psy­che­delics’ po­ten­tial to treat un­met needs in men­tal ill­ness­es — in­clud­ing post-trau­mat­ic stress dis­or­der, de­pres­sion, ad­dic­tion and anx­i­ety.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER